Literature DB >> 11070006

The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.

O Greengard1, N Poltoratskaia, E Leikina, J Zimmerberg, A Moscona.   

Abstract

4-GU-DANA (zanamivir) (as well as DANA and 4-AM-DANA) was found to inhibit the neuraminidase activity of human parainfluenza virus type 3 (HPF3). The viral neuraminidase activity is attributable to hemagglutinin-neuraminidase (HN), an envelope protein essential for viral attachment and for fusion mediated by the other envelope protein, F. While there is no evidence that HN's neuraminidase activity is essential for receptor binding and syncytium formation, we found that 4-GU-DANA prevented hemadsorption and fusion of persistently infected cells with uninfected cells. In plaque assays, 4-GU-DANA reduced the number (but not the area) of plaques if present only during the adsorption period and reduced plaque area (but not number) if added only after the 90-min adsorption period. 4-GU-DANA also reduced the area of plaques formed by a neuraminidase-deficient variant, confirming that its interference with cell-cell fusion is unrelated to inhibition of neuraminidase activity. The order-of-magnitude lower 50% inhibitory concentrations of 4-GU-DANA (and also DANA and 4-AM-DANA) for plaque area reduction and for inhibition in the fusion assay than for reducing plaque number or blocking hemadsorption indicate the particular efficacy of these sialic acid analogs in interfering with cell-cell fusion. In cell lines expressing influenza virus hemagglutinin (HA) as the only viral protein, we found that 4-GU-DANA had no effect on hemadsorption but did inhibit HA2b-red blood cell fusion, as judged by both lipid mixing and content mixing. Thus, 4-GU-DANA can interfere with both influenza virus- and HPF3-mediated fusion. The results indicate that (i) in HPF3, 4-GU-DANA and its analogs have an affinity not only for the neuraminidase active site of HN but also for sites important for receptor binding and cell fusion and (ii) sialic acid-based inhibitors of influenza virus neuraminidase can also exert a direct, negative effect on the fusogenic function of the other envelope protein, HA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070006      PMCID: PMC113191          DOI: 10.1128/jvi.74.23.11108-11114.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.

Authors:  A S Monto; D M Fleming; D Henry; R de Groot; M Makela; T Klein; M Elliott; O N Keene; C Y Man
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

2.  Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid.

Authors:  G P Thomas; M Forsyth; C R Penn; J W McCauley
Journal:  Antiviral Res       Date:  1994-08       Impact factor: 5.970

3.  The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.

Authors:  S Levin Perlman; M Jordan; R Brossmer; O Greengard; A Moscona
Journal:  Virology       Date:  1999-12-05       Impact factor: 3.616

4.  Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion.

Authors:  G W Kemble; T Danieli; J M White
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Comparison of transient and successful fusion pores connecting influenza hemagglutinin expressing cells to planar membranes.

Authors:  G B Melikyan; W D Niles; V A Ratinov; M Karhanek; J Zimmerberg; F S Cohen
Journal:  J Gen Physiol       Date:  1995-11       Impact factor: 4.086

6.  Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.

Authors:  K Huberman; R W Peluso; A Moscona
Journal:  Virology       Date:  1995-12-01       Impact factor: 3.616

7.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events.

Authors:  R Blumenthal; D P Sarkar; S Durell; D E Howard; S J Morris
Journal:  J Cell Biol       Date:  1996-10       Impact factor: 10.539

9.  Restricted movement of lipid and aqueous dyes through pores formed by influenza hemagglutinin during cell fusion.

Authors:  J Zimmerberg; R Blumenthal; D P Sarkar; M Curran; S J Morris
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

10.  Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers.

Authors:  T Danieli; S L Pelletier; Y I Henis; J M White
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

View more
  40 in total

1.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors:  Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.

Authors:  Matteo Porotto; Micaela Fornabaio; Olga Greengard; Matthew T Murrell; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.

Authors:  Matteo Porotto; Micaela Fornabaio; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Authors:  Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

5.  Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state.

Authors:  Matteo Porotto; Zuhair W Salah; Long Gui; Ilaria DeVito; Eric M Jurgens; Hong Lu; Christine C Yokoyama; Laura M Palermo; Kelly K Lee; Anne Moscona
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.

Authors:  G A Prince; M G Ottolini; A Moscona
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).

Authors:  Matthew Murrell; Matteo Porotto; Thomas Weber; Olga Greengard; Anne Moscona
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.

Authors:  M T Murrell; M Porotto; O Greengard; N Poltoratskaia; A Moscona
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.